448 related articles for article (PubMed ID: 31724047)
1. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.
Sato T; Yamawaki K
Clin Infect Dis; 2019 Nov; 69(Suppl 7):S538-S543. PubMed ID: 31724047
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. [Discovery of a New Siderophore Cephalosporin, Cefiderocol].
Yamano Y
Yakugaku Zasshi; 2024; 144(6):627-631. PubMed ID: 38825471
[TBL] [Abstract][Full Text] [Related]
4. Cefiderocol: A Siderophore Cephalosporin.
El-Lababidi RM; Rizk JG
Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
[TBL] [Abstract][Full Text] [Related]
5. An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria.
AlMatar M; Albarri O; Makky EA; Var I; Köksal F
Mini Rev Med Chem; 2020; 20(18):1908-1916. PubMed ID: 32811410
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
7.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
Aoki T; Yoshizawa H; Yamawaki K; Yokoo K; Sato J; Hisakawa S; Hasegawa Y; Kusano H; Sano M; Sugimoto H; Nishitani Y; Sato T; Tsuji M; Nakamura R; Nishikawa T; Yamano Y
Eur J Med Chem; 2018 Jul; 155():847-868. PubMed ID: 29960205
[TBL] [Abstract][Full Text] [Related]
9. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
10. Cefiderocol: a novel siderophore cephalosporin.
Choi JJ; McCarthy MW
Expert Opin Investig Drugs; 2018 Feb; 27(2):193-197. PubMed ID: 29318906
[TBL] [Abstract][Full Text] [Related]
11. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens.
Bonomo RA
Clin Infect Dis; 2019 Nov; 69(Suppl 7):S519-S520. PubMed ID: 31724046
[TBL] [Abstract][Full Text] [Related]
13. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
Kuai J; Wang X; Wang H
Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
[TBL] [Abstract][Full Text] [Related]
14.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
15. New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.
Nurjadi D; Kocer K; Chanthalangsy Q; Klein S; Heeg K; Boutin S
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0201121. PubMed ID: 34871093
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
17.
Ito A; Sato T; Ota M; Takemura M; Nishikawa T; Toba S; Kohira N; Miyagawa S; Ishibashi N; Matsumoto S; Nakamura R; Tsuji M; Yamano Y
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061741
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of cefiderocol.
Soriano A; Mensa J
Rev Esp Quimioter; 2022 Sep; 35 Suppl 2(Suppl 2):16-19. PubMed ID: 36193980
[TBL] [Abstract][Full Text] [Related]
19. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]